The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.
Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback